Lithium Ion

Lithium Ion

SCHEMBL1460434

CCCCNCCCC(C)N.[Li+].[NH2-]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.56
TP53 P04637 1/20 0.45
ALDH1A1 P00352 4/20 0.44
TSHR P16473 3/20 0.44
SLC15A1 P46059 1/20 0.36
ANPEP P15144 1/20 0.34
ERAP2 Q6P179 1/20 0.34
CYP2C19 P33261 2/20 0.33
ADH1B P00325 2/20 0.33
ADH1C P00326 2/20 0.33
ADH1A P07327 2/20 0.33
ADH7 P40394 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
SPHK1 Q9NYA1 1/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33
KMT2A Q03164 1/20 0.33
DPP7 Q9UHL4 1/20 0.32
CYP1A2 P05177 1/20 0.32
ADH4 P08319 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL12983285 0.94 OPRM1 (0.60) OPRM1TP53ALDH1A1TSHRSLC15A1
Lithium Ion SCHEMBL1459593 0.92 OPRM1 (0.58) OPRM1TP53ALDH1A1TSHRANPEP
Lithium Ion SCHEMBL1458552 0.92 OPRM1 (0.58) OPRM1TP53ALDH1A1TSHRANPEP
Lithium Ion SCHEMBL1459566 0.91 OPRM1 (0.50) OPRM1TP53ALDH1A1TSHRSLC15A1
Lithium Ion SCHEMBL1459203 0.89 OPRM1 (0.67) OPRM1TP53ALDH1A1TSHRANPEP
Lithium Ion SCHEMBL1459206 0.88 OPRM1 (0.64) OPRM1TP53ALDH1A1TSHRANPEP
SCHEMBL10643764 0.86 OPRM1 (0.54) OPRM1TP53ALDH1A1TSHRSLC15A1
SCHEMBL16208729 0.86 OPRM1 (0.54) OPRM1TP53ALDH1A1TSHRSLC15A1
SCHEMBL17508101 0.86 OPRM1 (0.50) OPRM1TP53ALDH1A1TSHRCYP2C19
Lithium Ion SCHEMBL1459212 0.85 OPRM1 (0.54) OPRM1TP53ALDH1A1TSHRSLC15A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729204-B2 Compositions and method for producing poly-aminofunctionalized polymerization initiators and corresponding polymers BRIDGESTONE CORPORATION (JP) 2014-05-20 US disclosed
EP-2475534-B1 COMPOSITIONS AND METHODS FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS BRIDGESTONE CORP (JP) 2013-10-23 EP disclosed
US-20120259056-A1 COMPOSITIONS AND METHOD FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS BRIDGESTONE CORPORATION (JP) 2012-10-11 US disclosed
EP-2475534-A1 COMPOSITIONS AND METHODS FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS Bridgestone Corporation (JP) 2012-07-18 EP disclosed
WO-2011031943-A1 COMPOSITIONS AND METHODS FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS BRIDGESTONE CORPORATION (JP) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120259056-A1 COMPOSITIONS AND METHOD FOR PRODUCING POLY-AMINOFUNCTIONALIZED POLYMERIZATION INITIATORS AND CORRESPONDING POLYMERS PARG, PARN, PAM OPRM1 2356/4885TP53 3609/4885ALDH1A1 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.